Current cancer drug targets

Keyphrases

Publications

volume 24, number 10, 2024

Qingqiong Luo, Sheng Hu, Yijie Tang, Dandan Yang, Qilong Chen
PPT1 Promotes Growth and Inhibits Ferroptosis of Oral Squamous Cell Carcinoma Cells. Current cancer drug targets 24 (10) (2024)
Yue Chong, Shan Xu, Tianjie Liu, Peng Guo, Xinyang Wang, Dalin He, Guodong Zhu
Curcumin Inhibits Vasculogenic Mimicry via Regulating ETS-1 in Renal Cell Carcinoma. Current cancer drug targets 24 (10) (2024)
Yongyin Gao, Hongdian Zhang, Yanli Qiu, Xueyan Bian, Xue Wang, Yue Li
Effect of Neoadjuvant Immunotherapy Combined with Chemotherapy on Pulmonary Function and Postoperative Pulmonary Complications in Esophageal Cancer: A Retrospective Study. Current cancer drug targets 24 (10) (2024)
Shuping Yang, Zhi Li, Mingyue Pan, Jing Ma, Zeyu Pan, Peng Zhang, Weiling Cao
Repurposing of Antidiarrheal Loperamide for Treating Melanoma by Inducing Cell Apoptosis and Cell Metastasis Suppression In vitro and In vivo . Current cancer drug targets 24 (10) (2024)
Biqing Chen, Yichao Wang, Yishi Wu, Tianmin Xu
Effect of HPV Oncoprotein on Carbohydrate and Lipid Metabolism in Tumor Cells. Current cancer drug targets 24 (10) (2024)

volume 24, number 5, 2024

Xiangyang Zhou, Di Wu, Linmiao Zhu, Ruohan Li, Haitao Yu, Wenjuan Li
Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis. Current cancer drug targets 24 (5) (2024)
Yuan Gao, Youling Li, Yunhe Zhu, Qiao Luo, Yifeng Lu, Ke Wen, Boyu Du, Xueyan Xi, Gang Li
Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer. Current cancer drug targets 24 (5) (2024)
Saijin Cui, Tianyu Chen, Yaning Zhao, Zhuoyun Xiao, Meitong Liu, Xi Huang, Shiru Cao, Rongmiao Zhou, You Li, Xiangran Huo, Na Wang
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy. Current cancer drug targets 24 (5) (2024)
Yuan Gao, Youling Li, Yunhe Zhu, Qiao Luo, Yifeng Lu, Ke Wen, Boyu Du, Xueyan Xi, Gang Li
Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer. Current cancer drug targets 24 (5) (2024)
Yujing Wu, Shuang Liu, Zhijuan Fan, Yaqiong Tian, Lei Zhang, Shuye Liu
Establishment and Validation of a Blood Test-based Nomogram to Diagnose Patients with AFP-negative HCC. Current cancer drug targets 24 (5) (2024)
Saijin Cui, Tianyu Chen, Yaning Zhao, Zhuoyun Xiao, Meitong Liu, Xi Huang, Shiru Cao, Rongmiao Zhou, You Li, Xiangran Huo, Na Wang
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy. Current cancer drug targets 24 (5) (2024)
Xiangyang Zhou, Di Wu, Linmiao Zhu, Ruohan Li, Haitao Yu, Wenjuan Li
Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis. Current cancer drug targets 24 (5) (2024)
Daxiang Liu, Wenjing Wang, Yanzhao Wu, Yongle Qiu, Lan Zhang
LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1. Current cancer drug targets 24 (5) (2024)
Saijin Cui, Tianyu Chen, Yaning Zhao, Zhuoyun Xiao, Meitong Liu, Xi Huang, Shiru Cao, Rongmiao Zhou, You Li, Xiangran Huo, Na Wang
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy. Current cancer drug targets 24 (5) (2024)
Yuan Gao, Youling Li, Yunhe Zhu, Qiao Luo, Yifeng Lu, Ke Wen, Boyu Du, Xueyan Xi, Gang Li
Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer. Current cancer drug targets 24 (5) (2024)
Xiangyang Zhou, Di Wu, Linmiao Zhu, Ruohan Li, Haitao Yu, Wenjuan Li
Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis. Current cancer drug targets 24 (5) (2024)
Yujing Wu, Shuang Liu, Zhijuan Fan, Yaqiong Tian, Lei Zhang, Shuye Liu
Establishment and Validation of a Blood Test-based Nomogram to Diagnose Patients with AFP-negative HCC. Current cancer drug targets 24 (5) (2024)
Yujing Wu, Shuang Liu, Zhijuan Fan, Yaqiong Tian, Lei Zhang, Shuye Liu
Establishment and Validation of a Blood Test-based Nomogram to Diagnose Patients with AFP-negative HCC. Current cancer drug targets 24 (5) (2024)
Daxiang Liu, Wenjing Wang, Yanzhao Wu, Yongle Qiu, Lan Zhang
LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1. Current cancer drug targets 24 (5) (2024)

volume 24, number 6, 2024

Zeynab Marzhoseyni, Zahra Shaghaghi, Maryam Alvandi, Maria Shirvani
Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer. Current cancer drug targets 24 (6) (2024)
Defang Ding, Jingyu Zhong, Yue Xing, Yangfan Hu, Xiang Ge, Weiwu Yao
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression. Current cancer drug targets 24 (6) (2024)
Ana Helena Larangeira Nóbrega, Rafael Sampaio Pimentel, Ana Paula Prado, Jenifer Garcia, Rudimar Luiz Frozza, Andressa Bernardi
Neuroinflammation in Glioblastoma: The Role of the Microenvironment in Tumour Progression. Current cancer drug targets 24 (6) (2024)
Zeynab Marzhoseyni, Zahra Shaghaghi, Maryam Alvandi, Maria Shirvani
Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer. Current cancer drug targets 24 (6) (2024)
Defang Ding, Jingyu Zhong, Yue Xing, Yangfan Hu, Xiang Ge, Weiwu Yao
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression. Current cancer drug targets 24 (6) (2024)
Ana Helena Larangeira Nóbrega, Rafael Sampaio Pimentel, Ana Paula Prado, Jenifer Garcia, Rudimar Luiz Frozza, Andressa Bernardi
Neuroinflammation in Glioblastoma: The Role of the Microenvironment in Tumour Progression. Current cancer drug targets 24 (6) (2024)
YuYe Du, Jia Lai, Jingyao Su, Jiali Li, Chuqing Li, Bing Zhu, Yinghua Li
Naringenin-induced Oral Cancer Cell Apoptosis Via ROS-mediated Bid and Bcl-xl Signaling Pathway. Current cancer drug targets 24 (6) (2024)
Wei Yang, Zelin Chen, Langfan Qu, Can Zhang, Hongdan Chen, Jiancheng Zheng, Wanchao Chen, Xu Tan, Chunmeng Shi
IR-780 Dye-based Targeting of Cancer-associated Fibroblasts Improves Cancer Immunotherapy by Increasing Intra-tumoral T Lymphocytes Infiltration. Current cancer drug targets 24 (6) (2024)

volume 24, number 7, 2024

Ye Zhang, Hai-Jiao Yan, Jun Wu
The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma. Current cancer drug targets 24 (7) (2024)
Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 24 (7) (2024)
Yanglong Guo, Xi Chen, Xuedong Tang, Shan Pan, Tao Zhu, Yingli Zhang
Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer. Current cancer drug targets 24 (7) (2024)
Shun Wan, Kun-Peng Li, Chen-Yang Wang, Jian-Wei Yang, Si-Yu Chen, Hua-Bin Wang, Xiao-Ran Li, Li Yang
Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer. Current cancer drug targets 24 (7) (2024)
Yiqi Du, Fenglin Zhang, Panling Xu, Ping Li
Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis. Current cancer drug targets 24 (7) (2024)
Yanglong Guo, Xi Chen, Xuedong Tang, Shan Pan, Tao Zhu, Yingli Zhang
Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer. Current cancer drug targets 24 (7) (2024)
Kelly C Arias Cardenas, Clinton W Enos, Mark R Spear, Dana E Austin, Raghad Almofeez, Stephanie Kortchak, Lauren Pincus, Hua-Bei Guo, Samuel Dolezal, J Michael Pierce, Emma Furth, Cyrille Gineste, Yongjun Kwon, Cohava Gelber
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells. Current cancer drug targets 24 (7) (2024)
Yiqi Du, Fenglin Zhang, Panling Xu, Ping Li
Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis. Current cancer drug targets 24 (7) (2024)

volume 24, number 8, 2024

Xinyang Li, Junshuai Rui, Zihan Yang, Feng Shang-Guan, Haolin Shi, Dengkui Wang, Jiachun Sun
Cuproptosis Related Gene DLD Associated with Poor Prognosis and Malignant Biological Characteristics in Lung Adenocarcinoma. Current cancer drug targets 24 (8) (2024)
Juntao Huang, Ziqian Xu, Zhenzhen Wang, Chongchang Zhou, Yi Shen
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma. Current cancer drug targets 24 (8) (2024)
Borui Xu, Jiahua Liang, Liangmin Fu, Jinhuan Wei, Juan Lin
A Novel Oncogenic Role of Disulfidptosis-related Gene SLC7A11 in Anti-tumor Immunotherapy Response to Human Cancers. Current cancer drug targets 24 (8) (2024)
Juntao Huang, Ziqian Xu, Zhenzhen Wang, Chongchang Zhou, Yi Shen
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma. Current cancer drug targets 24 (8) (2024)
Juntao Huang, Ziqian Xu, Zhenzhen Wang, Chongchang Zhou, Yi Shen
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma. Current cancer drug targets 24 (8) (2024)

volume 24, number 9, 2024

Yuan Meng, Meiying Zhu, Jie Yang, Xuerui Wang, Yangyueying Liang, Minghui Yu, Longhui Li, Fanming Kong
Treatment Advances in Lung Cancer with Leptomeningeal Metastasis. Current cancer drug targets 24 (9) (2024)
Baomin Zheng, Meilin He, Yaqian Han, Xin Jiang, Xiao-Min Ou, Peng Zhang, Ruyuan Guo, Jin-Gao Li, Xi-Mei Zhang, Qiao Qiao, Hui Wu, Man Hu, Mei Feng, Wenyong Tu, Jun-Lin Yi
Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis. Current cancer drug targets 24 (9) (2024)
Zongrui Xing, Xiangyan Jiang, Yuxia Wu, Zeyuan Yu
Targeted Mevalonate Pathway and Autophagy in Antitumor Immunotherapy. Current cancer drug targets 24 (9) (2024)
Vahideh Keyvani, Zari Naderi Ghale-Noie, Samaneh Mollazadeh, Reihaneh Alsadat Mahmoudian, Elnaz Ghorbani, Hamid Naderi, Majid Khazaei, Seyed Mahdi Hassanian, Gordon A Ferns, Amir Avan, Kazem Anvari
Recent Progress in the Application of Exosome Analysis in Ovarian Cancer Management. Current cancer drug targets 24 (9) (2024)
Gerhard Hamilton, Sandra Stickler, Barbara Rath
Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer. Current cancer drug targets 24 (9) (2024)
Reza Karbalaee, Saber Mehdizadeh, Hadi Esmaeili Gouvarchin Ghaleh, Morteza Izadi, Bahman Jalali Kondori, Ruhollah Dorostkar, Seyed Morteza Hosseini
The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Coxsackievirus A21 on Mouse Models of Colorectal Cancer. Current cancer drug targets 24 (9) (2024)
Yuan Meng, Meiying Zhu, Jie Yang, Xuerui Wang, Yangyueying Liang, Minghui Yu, Longhui Li, Fanming Kong
Treatment Advances in Lung Cancer with Leptomeningeal Metastasis. Current cancer drug targets 24 (9) (2024)
Wenjun Liang, Mingxia Yang, Xiaohua Wang, Yan Qian, Ruichen Gao, Yujia Shi, Xuejun Shi, Lei Shi, Ting Xu, Qian Zhang
Deubiquitylase USP31 Induces Autophagy and Promotes the Progression in Lung Squamous Cell Carcinoma Cells by Stabilizing E2F1 Expression. Current cancer drug targets 24 (9) (2024)
Mohsen Aliakbarian, Gordon A Ferns, Mahmoud Mohamadzadeh Shabestari, Amir Mahmoud Ahmadzadeh, Aref Abdollahzade, Hoda Rahimi, Rozita Khodashahi, Mohammad-Hassan Arjmand
Elucidating the Role of Pro-renin Receptors in Pancreatic Ductal Adenocarcinoma Progression: A Novel Therapeutic Target in Cancer Therapy. Current cancer drug targets 24 (9) (2024)
Yi Wang, Xianling Du, Hongqiang Xin, Ruimin Xu
Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Current cancer drug targets 24 (9) (2024)